New Zealand markets close in 4 hours 35 minutes

Twist Bioscience Corporation (TWST)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
56.05-2.83 (-4.81%)
At close: 04:00PM EDT
55.50 -0.55 (-0.98%)
After hours: 06:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close58.88
Open57.85
Bid55.99 x 100
Ask56.13 x 600
Day's range55.95 - 59.60
52-week range14.42 - 59.60
Volume1,129,816
Avg. volume1,163,873
Market cap3.264B
Beta (5Y monthly)1.80
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Twist Bioscience Announces Clinical Progression of Pure Biologics’ Antibody Candidate Discovered Using Twist’s Antibody Libraries

    SOUTH SAN FRANCISCO, Calif., July 18, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that the first patient has been dosed in Pure Biologics’ exploratory Phase 0 clinical study of PBA-0405. PBA-0405 is a fully human IgG1 antibody that was discovered using Twist Biopharma Solutions’ synthetic antibody phage display libraries. Twist Biopharma Solutions, a divis

  • Business Wire

    Twist Bioscience to Report Fiscal 2024 Third Quarter Financial Results on Friday, August 2, 2024

    SOUTH SAN FRANCISCO, Calif., July 11, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 third quarter ended June 30, 2024, before the opening of the market on Friday, August 2, 2024. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time

  • Business Wire

    Twist Bioscience Expands High-Throughput IgG Antibody Portfolio with Launch of CHO Express Antibodies

    SOUTH SAN FRANCISCO, Calif., July 10, 2024--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the expansion of its high-throughput antibody portfolio with the launch of a CHO cell line for Twist Express Antibodies. Twist also offers HEK293 expression Twist Express Antibodies.